Castle Biosciences, Inc. CSTL

Company Overview

Castle Biosciences, Inc. is a molecular diagnostics company focused on developing and commercializing genomic and clinicopathologic tests that inform treatment decisions for patients with cancer and other complex diseases. The company operates within the precision medicine and diagnostic testing industries, with an emphasis on providing actionable risk stratification and prognostic information to physicians. Its tests are designed to guide clinical decision-making, particularly in oncology and dermatology, by identifying disease aggressiveness and likelihood of progression.

Founded in 2008, Castle Biosciences initially focused on prognostic testing for melanoma and gradually expanded its portfolio through internal development and acquisitions. The company completed its initial public offering in 2020 and is listed on the NASDAQ under the ticker CSTL. Over time, it has evolved into a multi-product diagnostics platform serving dermatologists, oncologists, gastroenterologists, and other specialists across the United States.